Literature DB >> 15049512

Neuronal and glial expression of the multidrug resistance gene product in an experimental epilepsy model.

Alberto Lazarowski1, Alberto Javier Ramos, Hernán García-Rivello, Alicia Brusco, Elena Girardi.   

Abstract

1. Failure of anticonvulsive drugs to prevent seizures is a common complication of epilepsy treatment known as drug-refractory epilepsy but their causes are not well understood. It is hypothesized that the multidrug resistance P-glycoprotein (Pgp-170), the product of the MDR-1 gene that is normally expressed in several excretory tissues including the blood brain barrier, may be participating in the refractory epilepsy. 2. Using two monoclonal antibodies against Pgp-170, we investigated the expression and cellular distribution of this protein in the rat brain during experimentally induced epilepsy. Repeated seizures were induced in male Wistar rats by daily administration of 3-mercaptopropionic acid (MP) 45 mg/kg i.p. for either 4 days (MP-4) or 7 days (MP-7). Control rats received an equivalent volume of vehicle. One day after the last injection, rats were sacrificed and brains were processed for immunohistochemistry for Pgp-170. As it was previously described, Pgp-170 immunostaining was observed in some brain capillary endothelial cells of animals from control group. 3. Increased Pgp-170 immunoreactivity was detected in MP-treated animals. Besides the Pgp-170 expressed in blood vessels, neuronal, and glial immunostaining was detected in hippocampus, striatum, and cerebral cortex of MP-treated rats. Pgp-170 immunolabeled neurons and glial cells were observed in a nonhomogeneous distribution. MP-4 animals presented a very prominent Pgp-170 immunostaining in the capillary endothelium, surrounding astrocytes and some neighboring neurons while MP-7 group showed increased neuronal labeling. 4. Our results demonstrate a selective increase in Pgp-170 immunoreactivity in the brain capillary endothelial cells, astrocytes, and neurons during repetitive MP-induced seizures. 5. The role for this Pgp-170 overexpression in endothelium and astrocytes as a clearance mechanism in the refractory epilepsy, and the consequences of neuronal Pgp-170 expression remain to be disclosed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15049512     DOI: 10.1023/b:cemn.0000012726.43842.d2

Source DB:  PubMed          Journal:  Cell Mol Neurobiol        ISSN: 0272-4340            Impact factor:   5.046


  34 in total

Review 1.  AP-1 transcription factors: short- and long-term modulators of gene expression in the brain.

Authors:  K Pennypacker
Journal:  Int Rev Neurobiol       Date:  1998       Impact factor: 3.230

2.  Does P-glycoprotein predict response to chemotherapy?

Authors:  V Ling
Journal:  J Natl Cancer Inst       Date:  1989-01-18       Impact factor: 13.506

3.  Convulsant activity of homocysteine and other short-chain mercaptoacids: protection therefrom.

Authors:  H Sprince; C M Parker; J A Josephs; J Magazino
Journal:  Ann N Y Acad Sci       Date:  1969-09-30       Impact factor: 5.691

4.  Striatum adenosine A2 receptors are modified during seizure: effect of cyclopentyladenosine administration.

Authors:  L Giraldez; F Zanetti; E Girardi
Journal:  Neurochem Res       Date:  1999-10       Impact factor: 3.996

5.  In vivo evidence for P-glycoprotein-mediated transport of phenytoin at the blood-brain barrier of rats.

Authors:  H Potschka; W Löscher
Journal:  Epilepsia       Date:  2001-10       Impact factor: 5.864

6.  Overexpression of multiple drug resistance genes in endothelial cells from patients with refractory epilepsy.

Authors:  S M Dombrowski; S Y Desai; M Marroni; L Cucullo; K Goodrich; W Bingaman; M R Mayberg; L Bengez; D Janigro
Journal:  Epilepsia       Date:  2001-12       Impact factor: 5.864

7.  Drug resistance in epilepsy: expression of drug resistance proteins in common causes of refractory epilepsy.

Authors:  S M Sisodiya; W-R Lin; B N Harding; M V Squier; M Thom
Journal:  Brain       Date:  2002-01       Impact factor: 13.501

8.  Comparative anticonvulsant activity of some 2,3-benzodiazepine derivatives in rodents.

Authors:  Giovambattista De Sarro; Guido Ferreri; Pietro Gareri; Emilio Russo; Angela De Sarro; Rosaria Gitto; Alba Chimirri
Journal:  Pharmacol Biochem Behav       Date:  2003-02       Impact factor: 3.533

9.  Transient increase of P-glycoprotein expression in endothelium and parenchyma of limbic brain regions in the kainate model of temporal lobe epilepsy.

Authors:  Ulrike Seegers; Heidrun Potschka; Wolfgang Löscher
Journal:  Epilepsy Res       Date:  2002-10       Impact factor: 3.045

Review 10.  Transcriptional regulators of the human multidrug resistance 1 gene: recent views.

Authors:  Stéphane Labialle; Landry Gayet; Eric Marthinet; Dominique Rigal; Loris G Baggetto
Journal:  Biochem Pharmacol       Date:  2002-09       Impact factor: 5.858

View more
  13 in total

Review 1.  Mouse models of neurological disorders: a view from the blood-brain barrier.

Authors:  William A Banks
Journal:  Biochim Biophys Acta       Date:  2009-10-29

Review 2.  Neuroimmune Axes of the Blood-Brain Barriers and Blood-Brain Interfaces: Bases for Physiological Regulation, Disease States, and Pharmacological Interventions.

Authors:  Michelle A Erickson; William A Banks
Journal:  Pharmacol Rev       Date:  2018-04       Impact factor: 25.468

3.  Recovery of motor spontaneous activity after intranasal delivery of human recombinant erythropoietin in a focal brain hypoxia model induced by CoCl2 in rats.

Authors:  Amalia Merelli; Laura Caltana; Patricia Girimonti; Alberto Javier Ramos; Alberto Lazarowski; Alicia Brusco
Journal:  Neurotox Res       Date:  2010-11-30       Impact factor: 3.911

4.  Pharmacokinetics of substrate uptake and distribution in murine brain after nasal instillation.

Authors:  Candace L Graff; Rong Zhao; Gary M Pollack
Journal:  Pharm Res       Date:  2005-02       Impact factor: 4.200

5.  The Prevention and Reversal of a Phenytoin-Resistant Model by N-acetylcysteine Therapy Involves the Nrf2/P-Glycoprotein Pathway at the Blood-Brain Barrier.

Authors:  Qiankun Liu; You Wang; Dandan Tan; Yong Liu; Peng Zhang; Limin Ma; Minxue Liang; Yangmei Chen
Journal:  J Mol Neurosci       Date:  2022-08-26       Impact factor: 2.866

6.  The NMDAR subunit NR2B expression is modified in hippocampus after repetitive seizures.

Authors:  J Auzmendi; N González; Elena Girardi
Journal:  Neurochem Res       Date:  2008-08-27       Impact factor: 3.996

Review 7.  Nanotechnology for delivery of drugs to the brain for epilepsy.

Authors:  Margaret F Bennewitz; W Mark Saltzman
Journal:  Neurotherapeutics       Date:  2009-04       Impact factor: 7.620

8.  Differential expression of cerebellar metabotropic glutamate receptors mGLUR2/3 and mGLUR4a after the administration of a convulsant drug and the adenosine analogue cyclopentyladenosine.

Authors:  Elena Silvia Girardi; Juan Canitrot; Marta Antonelli; Nélida N González; Héctor Coirini
Journal:  Neurochem Res       Date:  2007-03-31       Impact factor: 4.414

9.  Early Gabapentin Treatment during the Latency Period Increases Convulsive Threshold, Reduces Microglial Activation and Macrophage Infiltration in the Lithium-Pilocarpine Model of Epilepsy.

Authors:  Alicia Rossi; Veronica Murta; Jerónimo Auzmendi; Alberto Javier Ramos
Journal:  Pharmaceuticals (Basel)       Date:  2017-11-28

Review 10.  Drug-Resistant Epilepsy: Multiple Hypotheses, Few Answers.

Authors:  Fei Tang; Anika M S Hartz; Björn Bauer
Journal:  Front Neurol       Date:  2017-07-06       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.